#protease inhibitor

Resistance to four HIV drug classes is tied to high risk of disease and death.

Two-drug antiretroviral regimens suppress viral load, but three-drug combos may offer additional benefits.

Researchers at George Washington University take a look.

This from a small study of people who switched from a boosted protease inhibitor to Isentress (raltegravir) or Tivicay (dolutegravir).

Protease inhibitors, including those used for hep C, and various other drugs may cause drug-drug interactions with statins.

Among those taking Epivir, taking two antiretrovirals instead of three was tied to fewer people stopping because of side effects.

A recent analysis of Europeans taking boosted protease inhibitors for HIV treatment found this pair prompted the best long-term response.

In a small study, the drop in seminal viral load in men who started treatment with PIs lagged behind that of men going on other HIV meds.

Findings suggest that the older class of HIV drugs may contribute to HIV-associated neurocognitive disorders.